Navigation Links
Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
Date:9/5/2012

EAST BRUNSWICK, N.J., Sept. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Louis Ferrari, President and Chief Executive Officer of Savient, will present at the 6th Annual Imperial Capital Global Opportunities Conference on Thursday, September 20th at 10:30am Eastern Time at the Waldorf=Astoria Hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact:Mary Coleman

Caitlyn MurphySavient Pharmaceuticals, Inc.

Burns McClellaninformation@savient.com

cmurphy@burnsmc.com (732) 418-9300

(212) 213-0006


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
2. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
3. Savient Pharmaceuticals Adopts Stockholder Rights Plan
4. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
5. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
6. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
7. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
8. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
9. Questcor Pharmaceuticals to Present at Investor Conferences in September
10. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
(Date:4/29/2016)... 29, 2016 Acquisition Expands ... Product Development Capabilities in North America ... . Indegene ( http://www.indegene.com ), ... acquisition of Skura Corporation,s life science business. Skura,s ... sales enablement technology for life science organizations and ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... As directed by ... of Pennsylvania (HAP) issues its full support to allow certified nurse practitioners (CNP) to ... after they have worked under such supervision for three years and 3,600 hours. , ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s ... eating, mood and anxiety disorders, has rebranded its eating disorder program under a new ... eating disorder treatment facility on May 16. , To celebrate, ERC Chicago will ...
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident ... Main Residency Match® (“the Match”), the system through which U.S. and international medical ... record-high 30,750 positions were placed in the 2016 Match, and 29,572 were filled ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , ... can visit Dr. Assili to receive any dental extraction treatment for $40 off the ... June 30, 2016. With the lower price, patients can more easily afford extractions to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Zitter Health Insights ... Patient Satisfaction Award that will recognize specialty pharmacies for their achievements in customer ... Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results will be published ...
Breaking Medicine News(10 mins):